NOVN Novan Inc.

0.4
+0.02  (+6%)
Previous Close 0.38
Open 0.39
Price To Book -1.14
Market Cap 26,897,541
Shares 67,361,736
Volume 3,729,201
Short Ratio
Av. Daily Volume 11,104,457
Stock charts supplied by TradingView

NewsSee all news

  1. Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement

    Per verbal guidance, FDA to consider one additional pivotal trialFDA-generated minutes expected on or before May 1, 2020Sato Pharmaceutical to begin start-up of Phase 1 trial in Japan MORRISVILLE, N.C., April 03,

  2. Novan Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market

    MORRISVILLE, N.C., March 26, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company's previously announced registered direct offering

  3. Novan Announces $8.0 Million Registered Direct Offering Priced At-the-Market

    MORRISVILLE, N.C., March 24, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it has entered into definitive agreements with several institutional and

  4. Novan Announces Data from B-SIMPLE Week 24 Safety Evaluation and COVID-19 Business Updates

    Favorable SB206 Week 24 safety and scarring profilesType C teleconference with FDA for SB206 remains scheduled on April 1, 2020Novan intends to screen NVN1000 against a number of viruses, including SARS-CoV-2

  5. Novan Announces Closing of $5.95 Million Public Offering, including Partial Exercise of the Underwriter's Option to Purchase Additional Securities

    MORRISVILLE, N.C., March 03, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company's previously announced underwritten public offering of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data released November 29, 2016. Primary endpoint met.
SB206
Human papillomavirus (HPV)
Phase 2 data released April 12, 2017. Primary endpoint met.
SB208
Fungal infections
Phase 3 top-line data released January 27, 2017. Met one of three co-primary endpoints in NI-AC301 trial. Met all endpoints in NI-AC302 trial. Additional Phase 3 trial required.
SB204
Acne vulgaris
Phase 3 data did not meet primary endpoint - January 2, 2020.
SB206
Molluscum contagiosum skin infection
Phase 2 trial to be initiated 4Q 2019.
SB414
Atopic Dermatitis

Latest News

  1. Novan Receives Verbal Guidance from FDA for SB206 and Announces Sato Program Advancement

    Per verbal guidance, FDA to consider one additional pivotal trialFDA-generated minutes expected on or before May 1, 2020Sato Pharmaceutical to begin start-up of Phase 1 trial in Japan MORRISVILLE, N.C., April 03,

  2. Novan Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market

    MORRISVILLE, N.C., March 26, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company's previously announced registered direct offering

  3. Novan Announces $8.0 Million Registered Direct Offering Priced At-the-Market

    MORRISVILLE, N.C., March 24, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it has entered into definitive agreements with several institutional and

  4. Novan Announces Data from B-SIMPLE Week 24 Safety Evaluation and COVID-19 Business Updates

    Favorable SB206 Week 24 safety and scarring profilesType C teleconference with FDA for SB206 remains scheduled on April 1, 2020Novan intends to screen NVN1000 against a number of viruses, including SARS-CoV-2

  5. Novan Announces Closing of $5.95 Million Public Offering, including Partial Exercise of the Underwriter's Option to Purchase Additional Securities

    MORRISVILLE, N.C., March 03, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company's previously announced underwritten public offering of

  6. Novan Announces Pricing of $5.5 Million Public Offering

    MORRISVILLE, N.C., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's previously announced underwritten public

  7. Novan Announces Proposed Public Offering

    MORRISVILLE, N.C., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it intends to offer and sell a combination of shares of its common stock (or pre-funded

  8. Novan Receives Phase 2 NIH Federal Grant of Approximately $1.0 Million

    Provides funds to evaluate the mechanistic antiviral activity of WH602Novan to progress IND-enabling toxicology and pharmacology studies for WH602 Grant is additive to $223,000 Phase 1 NIH grant received in August

  9. Novan Provides SB206 Program and Business Update

    FDA grants Type C meeting for SB206 to be held on April 1, 2020Last subject completes last visit, Week 24 safety evaluationAdditional 12-week efficacy and safety data provided MORRISVILLE, N.C., Feb. 06, 2020 (GLOBE

  10. Novan Reports Top-Line Efficacy Results from Phase 3 Trials of SB206 for Molluscum Contagiosum

    Company to hold conference call Friday, January 3, 2020 at 8:30 am Eastern TimeFocus of call: top-line efficacy data and sensitivity analyses MORRISVILLE, N.C., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. ("the

  11. Novan Announces Planned Chief Executive Officer Transition

    Paula Brown Stafford appointed as CEO effective February 2, 2020G. Kelly Martin's term as CEO will end on February 1, 2020, per his employment contractMr. Martin will step down from the Novan Board of Directors effective

  12. François Nader, M.D., Joins Moderna's Board of Directors

    Former CEO of NPS Pharmaceuticals brings broad expertise to support Moderna's progress towards late-stage development and commercialization

  13. Novan's Phase 2 SB206 Molluscum Study Published in Journal of the American Academy of Dermatology

    MORRISVILLE, N.C., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the Company's Phase 2 molluscum study, designed to evaluate topical nitric

  14. Novan Awarded Approximately $1.1 Million Grant by Department of Defense

    Funds to progress women's health product candidate, WH504Additive to recently announced NIH grant for WH602Women's health initiative to focus on potential HPV related onco-virus therapeutics MORRISVILLE, N.C., Sept.

  15. Novan Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    MORRISVILLE, N.C., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the Compensation Committee of Novan's Board of Directors granted stock

  16. Novan and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $25 Million

    MORRISVILLE, N.C., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the Company has entered into a Common Stock Purchase Agreement (the

  17. Novan Hires Michelle Patterson as Vice President of Project Management

    Underscores Company's preparation for potential NDA submission for SB206 in molluscumRole to lead cross-functional coordination of key activities and timelines for the programSB206 top line results are expected no later

  18. Novan to Participate in H.C. Wainwright 21st Annual Global Investment Conference

    MORRISVILLE, N.C., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that it will participate in the H.C. Wainwright 21st Annual Global Investment